Please assess the completion status of the following clinical trial:

Trial Title: Safety of BBB Opening With the SonoCloud

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Age greater than 18 years.~* Subjects with recurrent glioma who have failed standard therapy with surgery and/or treatment with radiation and temozolomide.~* Patient eligible for Carboplatin-based chemotherapy~* Contrast-enhanced tumor less than 35 mm in diameter~* No risk of cerebral herniation~* Able to tolerate pre/post procedure steroid treatment~* Social security affiliated (in France)~* Able and willing to give signed and informed consent~* Normal biological status~* Hemoglobin ≥ 10 g/dl~* Platelets ≥ 100000/mm3~* Neutrophils ≥ 1500/mm3~* Normal creatine clearance ≥ 60ml/mn~* ASAT \< 3 N~* ALAT \< 3 N~* Normal Bilirubin Level \< 1.5 N~* Alkaline Phosphatase \< 3 N~* INR \< 1.5~* Prothrombin Level ≥ 70%~Exclusion criteria:~* Allergic to Iodine, Gadolinium, Xylocain~* Contra-indications to echographic contrast agent (microbubbles)~* Severe Renal insufficiency~* Hepatic insufficiency~* Possible toxic treatment for CNS~* Previously infected surgical field~* Uncontrolled epilepsy~* MRI contra-indications~* Hemostasis troubles thrombopenia \<75.000, TP \<60%, INR \>1.5, anti-platelet or anticoagulant therapy on-going)~* Active phlebitis or active pulmonary embolism~* Pregnant or currently breast-feeding~* Patients under judicial protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SonoCloud + carboplatin (Type: EXPERIMENTAL): SonoCloud : dose escalation Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC

Based on this trial design, predict the completion outcome and termination type (if applicable).